Drug Type Small molecule drug |
Synonyms 1-(3-chlorophenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}urea, SNS 314 |
Target |
Action inhibitors |
Mechanism AURK inhibitors(Serine/threonine-protein kinase Aurora inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H19ClN6O4S3 |
InChIKeyFYCODPVDEFFWSR-UHFFFAOYSA-N |
CAS Registry1146618-41-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Aug 2007 |
NCT00519662 (Literature) Manual | Phase 1 | 32 | lrvblhzoaa(xqdvvjefck) = gfiocfjfnl fdfuqlqzbb (tvoywonmft ) View more | Positive | 20 May 2009 |